Literature DB >> 15852461

Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease.

Nancy S Foldi1, Richard E C White, Lynn A Schaefer.   

Abstract

BACKGROUND: Attentional function is impaired in Alzheimer's disease (AD). Moreover, attention is mediated by acetylcholine. But, despite the widespread use of acetylcholinesterase inhibitors (AChE-I) to augment available acetylcholine in AD, measures of attentional function have not been used to assess the drug response.
OBJECTIVES: We hypothesized that as cholinergic augmentation impacts directly on the attentional system, higher-order measures of visual selective attention would be sensitive to effects of treatment using an AChE-I (donepezil hydrochloride). We also sought to determine whether these attentional measures were more sensitive to treatment than other measures of cognitive function.
METHODS: Seventeen patients with AD (8 untreated, 9 treated with donepezil) were contrasted on performance of a selective cancellation task. Two signal detection parameters were used as outcome measures: decision strategy (beta, beta) and discriminability (d-prime, d'). Standard screening and cognitive domain measures of vigilance, language, memory, and executive function were also contrasted.
RESULTS: Treated patients judged stimuli more conservatively (p = 0.29) by correctly endorsing targets and rejecting false alarms. They also discriminated targets from distractors more easily (p = 0.58). The screening and neuropsychological measures failed to differentiate the groups.
CONCLUSIONS: Higher-order attentional measures captured the effects of donepezil treatment in small groups of patients with AD. The results suggest that cholinergic availability may directly affect the attentional system, and that these selective attention measures are sensitive markers to detect treatment response. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852461     DOI: 10.1002/gps.1319

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  17 in total

1.  Beneficial effects of electrostimulation contingencies on sustained attention and electrocortical activity.

Authors:  Max Jean-Lon Chen; Trevor Thompson; Juri Kropotov; John H Gruzelier
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

Review 2.  Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors:  J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal:  J Autism Dev Disord       Date:  2007-01-13

3.  Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease.

Authors:  Lori A Daiello; Brian R Ott; Elena K Festa; Michael Friedman; Lindsay A Miller; William C Heindel
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

Review 4.  Modes and models of forebrain cholinergic neuromodulation of cognition.

Authors:  Michael E Hasselmo; Martin Sarter
Journal:  Neuropsychopharmacology       Date:  2010-07-28       Impact factor: 7.853

5.  Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept).

Authors:  Carola Romberg; Mark P Mattson; Mohamed R Mughal; Timothy J Bussey; Lisa M Saksida
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

Review 6.  Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment.

Authors:  Rebecca L Ashare; Mary Falcone; Caryn Lerman
Journal:  Neuropharmacology       Date:  2013-04-29       Impact factor: 5.250

7.  Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial.

Authors:  Clara Vila-Castelar; Jenny J Ly; Lillian Kaplan; Kathleen Van Dyk; Jeffrey T Berger; Lucy O Macina; Jennifer L Stewart; Nancy S Foldi
Journal:  Arch Clin Neuropsychol       Date:  2019-05-01       Impact factor: 2.813

8.  MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.

Authors:  Adam C Mar; Simon R O Nilsson; Begoña Gamallo-Lana; Ming Lei; Theda Dourado; Johan Alsiö; Lisa M Saksida; Timothy J Bussey; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2017-07-26       Impact factor: 4.530

9.  Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.

Authors:  Paul Bentley; Jon Driver; Ray J Dolan
Journal:  Brain       Date:  2007-12-12       Impact factor: 13.501

10.  A touch screen-automated cognitive test battery reveals impaired attention, memory abnormalities, and increased response inhibition in the TgCRND8 mouse model of Alzheimer's disease.

Authors:  Carola Romberg; Alexa E Horner; Timothy J Bussey; Lisa M Saksida
Journal:  Neurobiol Aging       Date:  2012-09-05       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.